Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
50.90
+0.76 (1.52%)
At close: Oct 3, 2025, 4:00 PM EDT
50.27
-0.63 (-1.24%)
After-hours: Oct 3, 2025, 7:11 PM EDT
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
$648,117
Profits / Employee
$129,317
Market Cap
124.04B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
Dec 31, 2020 | 99,412 | -997 | -0.99% |
Dec 31, 2019 | 100,409 | -3,817 | -3.66% |
Dec 31, 2018 | 104,226 | -2,340 | -2.20% |
Dec 31, 2017 | 106,566 | -293 | -0.27% |
Dec 31, 2016 | 106,859 | -2,230 | -2.04% |
Dec 31, 2015 | 109,089 | 1,702 | 1.58% |
Dec 31, 2014 | 107,387 | -4,741 | -4.23% |
Dec 31, 2013 | 112,128 | 154 | 0.14% |
Dec 31, 2012 | 111,974 | -1,745 | -1.53% |
Dec 31, 2011 | 113,719 | 12,144 | 11.96% |
Dec 31, 2010 | 101,575 | -3,292 | -3.14% |
Dec 31, 2009 | 104,867 | 6,654 | 6.78% |
Dec 31, 2008 | 98,213 | -1,282 | -1.29% |
Dec 31, 2007 | 99,495 | -794 | -0.79% |
Dec 31, 2006 | 100,289 | 3,108 | 3.20% |
Dec 31, 2005 | 97,181 | 742 | 0.77% |
Dec 31, 2004 | 96,439 | 63,353 | 191.48% |
Dec 31, 2003 | 33,086 | 650 | 2.00% |
Dec 31, 2002 | 32,436 | 1,922 | 6.30% |
Dec 31, 2001 | 30,514 | 1,314 | 4.50% |
Dec 31, 2000 | 29,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SNY News
- 15 hours ago - Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade) - Seeking Alpha
- 3 days ago - Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes - Business Wire
- 4 days ago - QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials - Business Wire
- 9 days ago - A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff - Seeking Alpha
- 9 days ago - Sanofi Expands Insulin Savings Program To Cover All US Patients - Benzinga
- 9 days ago - Sanofi to offer all insulin products for $35 per month in US - Reuters
- 9 days ago - Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US - PRNewsWire
- 11 days ago - French court orders Sanofi to pay $177 million for anti-competitive behaviour - Reuters